Bristol-Myers Squibb

Saladax Biomedical expands collaboration with BMS

Monday, August 6, 2012 12:23 PM

Saladax Biomedical, a developer of novel diagnostic assays, has expanded its existing relationship with Bristol-Myers Squibb by entering into a Master Early Development Collaboration Agreement, which may include multiple feasibility studies and companion diagnostic development projects. 

More... »

Teva appoints two to executive team

Friday, August 3, 2012 11:07 AM

Teva Pharmaceutical, a global pharmaceutical company based in Israel, has appointed Dr. Carlo De Notaristefani as president and CEO of global operations and Aharon (Arik) Yaari as executive vice president of newly created community and institutional affairs.

More... »

Prosetta, BMS form multi-year antiviral drug development collaboration

Wednesday, August 1, 2012 01:56 PM

Prosetta Antiviral, a San Francisco-based biotechnology company, has formed a strategic alliance with global biopharmaceutical company Bristol-Myers Squibb (BMS) to further discover and develop select drug candidates representing new, novel classes of antiviral drugs.

More... »

BMS Foundation marks World Hepatitis Day with new grants

Friday, July 27, 2012 11:22 AM

The Bristol-Myers Squibb Foundation has awarded four new grants totaling $1.69 million to improve prevention, care and support of hepatitis B (HBV) and hepatitis C (HCV) in China and India as part of its Delivering Hope program.

More... »

Genentech and Novartis rank as image leaders among oncologists, hematologists

Wednesday, July 25, 2012 09:59 AM

Genentech and Novartis have the best image among oncologists and hematologists, according to Market Strategies International, a market research consultancy that recently completed its 2012 Oncology Image Study.

More... »

BMS acquires Amylin Pharmaceuticals, expands diabetes alliance with AZ

Monday, July 2, 2012 09:59 AM

Global biopharmaceutical company Bristol-Myers Squibb (BMS) has agreed to acquire Amylin Pharmaceuticals of San Diego for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion.

More... »

Scripps Research inks 5-year research collaboration with BMS

Friday, June 15, 2012 03:37 PM

The Scripps Research Institute, an independent, not-for-profit organization focused on research in the biomedical sciences, has entered into a five-year collaboration with Bristol-Myers Squibb (BMS) focusing on applying novel chemistry to drug discovery and synthesis.

More... »

Cell Therapeutics appoints Benner as new CMO

Friday, June 15, 2012 11:11 AM

Cell Therapeutics, a Seattle-based company focused on translating science into novel cancer therapies, has appointed former OncoMed Pharmaceuticals executive, Steven E. Benner, M.D., M.H.S., as its executive vice president and chief medical officer.

More... »

BMS announces global collaboration for immuno-oncology

Wednesday, May 30, 2012 02:43 PM

Global biopharmaceutical company Bristol-Myers Squibb has announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology (harnassing the body’s own immune system to fight cancer).

More... »

BMS Foundation expands Together on Diabetes to China and India

Friday, May 25, 2012 11:08 AM

The Bristol-Myers Squibb Foundation will be expanding its Together on Diabetes initiative to China and India, pledging $15 million over five years to help these developing nations with rapidly growing numbers of type 2 diabetes patients.

More... »